Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | SMO | Q99835 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.55 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782804 | 0.90 | MAPK14 (0.73) | MAPK14SMOHTTMAPTMAPK1 | |
| SCHEMBL6484389 | 0.85 | MAPK14 (0.70) | MAPK14SMOHTTMAPTRAB9A | |
| SCHEMBL6478056 | 0.85 | MAPK14 (0.68) | MAPK14SMOHTTMAPTRAB9A | |
| SCHEMBL6485580 | 0.85 | MAPK14 (0.75) | MAPK14TDP1SMOHTTMAPT | |
| SCHEMBL7780464 | 0.83 | MAPK14 (0.65) | MAPK14SMOHTTMAPTRAB9A | |
| SCHEMBL6488842 | 0.82 | MAPK14 (0.71) | MAPK14SMOHTTKMT2AMEN1 | |
| SCHEMBL6476817 | 0.81 | MAPK14 (0.63) | MAPK14SMOMAPTNPC1RAB9A | |
| SCHEMBL6488111 | 0.81 | MAPK14 (0.63) | MAPK14SMOLMNAKMT2AMEN1 | |
| SCHEMBL7809567 | 0.81 | MAPK14 (0.67) | MAPK14SMO | |
| SCHEMBL6780689 | 0.81 | MAPK14 (0.64) | MAPK14SMOKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| CN-1142912-C | Amide derivs. useful as inhibitors of production of cytokines | — | 2004-03-24 | — | — | CN | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| CN-1321150-A | Amide derivs. useful as inhibitors of production of cytokines | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | MAPK14 2563/4885TDP1 3213/4885SMO 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.